Synthetic composition and method for modulating brain function and behaviour
A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
1. A method for treating anxiety in a patient with irritable bowel syndrome (IBS), comprising orally administering to the patient an effective amount of a synthetic composition comprising one or more neutral human milk oligosaccharides (HMOs), wherein the amount is effective to increase the abundance of Bifidobacterium of the B. adolescentis phylogenetic group in the IBS patient.
2. The method according to claim 1 , wherein the patient is administered a higher amount of the one or more neutral HMOs for an initial treatment period, followed by a lower amount of the one or more neutral HMOs, for a maintenance period.
3. The method according to claim 1 , wherein the neutral HMO is selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and lacto-N-fucopentaose I (LNFP-I).
4. The method according to claim 1 , wherein the synthetic composition comprises one or more neutral non-fucosylated HMOs and one or more neutral fucosylated HMOs.
5. The method according to claim 4 , wherein the synthetic composition comprises 2′-FL and/or DFL, and LNnT and/or LNT.
6. The method according to claim 1 , wherein the Bifidobacterium of the B. adolescentis phylogenetic group is Bifidobacterium adolescentis and/or Bifidobacterium pseudocatenulatum.
7. The method of claim 1 , wherein the patient exhibits one or more symptoms of depression, stress, bacterial overgrowth, dysbiosis, or impaired mucosal barrier.
8. The method according to claim 2 , wherein the initial treatment period is one to eight weeks.
9. The method according to claim 2 , wherein the maintenance period is at least one month.
10. The method according to claim 5 , wherein the synthetic composition comprises 2′-FL and LNT.
11. The method according to claim 5 , wherein the synthetic composition comprises 2′-FL, DFL and LNnT.
12. The method according to claim 1 , wherein the synthetic composition further comprises a diluent, excipient, antioxidant, lubricant, colorant, binder, disintegrant or a mixture thereof.
13. The method according to claim 1 , wherein the synthetic composition is a nutritional composition further comprising folic acid.
14. The method according to claim 1 , wherein the synthetic composition consists of one or more neutral HMOs.
15. The method according to claim 14 , wherein the neutral HMO is selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and lacto-N-fucopentaose I (LNFP-I).
16. The method according to claim 14 , wherein the one or more neutral HMOs consists of two or more neutral HMOs consisting of one or more neutral non-fucosylated HMOs and one or more neutral fucosylated HMOs.
17. The method according to claim 16 , wherein the synthetic composition consists of 2′-FL and LNT.
18. The method according to claim 16 , wherein the synthetic composition consists of 2′-FL, DFL and LNnT.
19. A method for treating anxiety in a patient with irritable bowel syndrome (IBS), comprising orally administering to the patient an effective amount of a synthetic composition comprising one or more neutral human milk oligosaccharides (HMOs),
wherein the patient is administered a higher amount of the one or more neutral HMOs for an initial treatment period, followed by a lower amount of the one or more neutral HMOs, for a maintenance period, and
wherein the initial treatment period comprises administering 5 g to 10 g per day of the one or more neutral HMOs.
20. A method for treating anxiety in a patient with irritable bowel syndrome (IBS), comprising orally administering to the patient an effective amount of a synthetic composition comprising one or more neutral human milk oligosaccharides (HMOs),
wherein the patient is administered a higher amount of the one or more neutral HMOs for an initial treatment period, followed by a lower amount of the one or more neutral HMOs, for a maintenance period, and
wherein the maintenance period comprises administering 1 g to 5 g per day of the one or more neutral HMOs.